Article Text

Download PDFPDF
Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study
  1. Julian A Luetkens1,
  2. Sabine Klein2,
  3. Frank Traeber1,
  4. Frederic C Schmeel1,
  5. Alois M Sprinkart1,
  6. Daniel L R Kuetting1,
  7. Wolfgang Block1,
  8. Kanishka Hittatiya3,
  9. Frank E Uschner2,
  10. Robert Schierwagen2,
  11. Juergen Gieseke1,4,
  12. Hans H Schild1,
  13. Jonel Trebicka2,5,6,7,
  14. Guido M Kukuk1
  1. 1 Department of Radiology, University of Bonn, Bonn, Germany
  2. 2 Department of Internal Medicine I, University of Bonn, Bonn, Germany
  3. 3 Institute of Pathology, University of Bonn, Bonn, Germany
  4. 4 Philips Research, Hamburg, Germany
  5. 5 European Foundation for the Study of Chronic Liver Failure, Barcelona, Spain
  6. 6 Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
  7. 7 Institute for Bioengineering of Catalonia, Barcelona, Spain
  1. Correspondence to Dr Jonel Trebicka, Department of Internal Medicine I, University of Bonn, Bonn 53113, Germany; jonel.trebicka{at}

Statistics from

We read with interest the recent reviews published in Gut, emphasising that even though the understanding of the pathobiology of liver fibrosis has been improved in the last three decades,1 novel and easy to implement diagnostic and therapeutic approaches are required.2 Indeed, fibrosis is the most important histological feature of patients with chronic liver disease (CLD), such as non-alcoholic fatty liver disease, and is associated with long-term overall mortality, liver transplantation and liver-related events.3 Diagnostic and therapeutic approaches,2 therefore, require accurate measurements that ideally allow non-invasive fibrosis quantification, representing the whole liver free of bias and easily integrated in clinical routine.

A liver biopsy, still the reference standard, has substantial drawbacks (complications, intraobserver and interobserver variabilities).4 Transient elastography (TE), suggested for population-wide screens (eg, patients with diabetes),5 requires additional expensive devices and trained personnel. However, contrast-enhanced MRI is routinely performed and recommended in patients with CLD for exclusion of hepatocellular …

View Full Text


  • JAL and SK contributed equally.

  • JT and GMK contributed equally.

  • Contributors JAL, SK, JT and GMK: concept, design, planning, analysis and drafting of the letter. FT, FCS, AMS, DLRK, WB, FEU, RS, JG and HHS: analysis, recruitment and critical revision of the letter.

  • Competing interests None declared.

  • Ethics approval Ethics committee of the University of Bonn.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.